venetoclax
venetoclax: sourced relationships with 2 companies · 162 clinical trials tracked · 2 FDA decisions.
venetoclax evidence translation
What we can confirm
2 FDA records · 162 tracked trials
What it means
What to watch
Prepared research question
What is verified about venetoclax, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 14 study sponsors
Related indications
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| AbbVie Inc. (ABBV) Reported 2016-04-11 · Current development: unknownSource Acute Myeloid Leukemia (AML); Diffuse Large B-cell Lymphoma;… | Phase 4 |
| DR REDDYS LABORATORIES LTD (RDY) Reported 2026-05-15 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (162)showing 10 most recent
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
Primary endpoint: Rate of Participants Achieving Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD) in Bone Marrow
A Phase 1b Dose Escalation and Dose Expansion Study of CLN 049 in Combination With Azacitidine and Venetoclax for the Treatment of Adult Patients With Newly Diagnosed, Acute Myeloid Leukemia
Primary endpoint: Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs) [safety and tolerability] of CLN-049 combined with azacitidine and venetoclax
A Phase Two Study of Venetoclax Plus Zanubrutinib in Newly Diagnosed CLL and After Front-Line Time-Limited Venetoclax-Based Therapy
Primary endpoint: Rate of undetectable minimal residual disease (uMRD) (Firstline Cohort)
A Phase 2 Study of Nemtabrutinib and Venetoclax as Frontline Treatment for Chronic Lymphocytic Leukemia (CLL)
Primary endpoint: Presence of undetectable minimal residual disease (MRD)
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated/Deleted AML Patients
Primary endpoint: Phase 2 Dose Level determination
An Open-label, Multicenter Phase 1b/2 Study to Evaluate the Safety and Efficacy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Primary endpoint: Number of participants with treatment-emergent adverse events
A Two Cohort, Randomized, Double-Blind, Placebo-Controlled, Phase II Multi-Center Signal-Finding Study of Venetoclax Combined With Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Cell Transplantation Then Venetoclax Maintenance in Adult Patients With Acute Myeloid Leukemia in First Complete Remission: A MyeloMATCH Sub-Study
Primary endpoint: Event free survival (EFS)
Immune-targeted Combination With Acute Lymphoblastic Leukemia-like Chemotherapy for Adult of Acute Leukemia of Ambiguous Lineage: A Prospective, Single-arm, Multicenter Clinical Study
Primary endpoint: overall survival (OS)
A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination With Venetoclax and Azacitidine in Adult Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy
Primary endpoint: Phase 2: Complete remission (CR)
The MAVRiC Study: A Phase II Study of Disease Risk Mutation Guided Finite Duration Acalabrutinib Plus Venetoclax for Relapse in CLL/SLL After First-line Finite Covalent BTKi Plus BCL2i Combination, With or Without Obinutuzumab
Primary endpoint: Overall Response Rate (ORR)
FDA Decisions2 records
Frequently asked questions
Which companies have sourced relationships with venetoclax?
venetoclax has dated SEC/FDA relationship records for AbbVie Inc., DR REDDYS LABORATORIES LTD.
How many clinical trials involve venetoclax?
BioSniper tracks 162 clinical trials involving venetoclax.
What is venetoclax's latest FDA decision?
The most recent tracked FDA decision for venetoclax is Approval, dated May 15, 2026.